New York · NY, USA · founded 2020 · https://kingdomsuperculture.com
Diligence memoA one-page analyst read on Kingdom — recommendation, valuation, rhythm, risks.→Kingdom: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Natural functional ingredients that actually work
Kingdom creates and sells Superculture® ingredients. Our Superculture® ingredients are an entirely new class of clinically-validated postbiotics that target the root causes of unmet pet health needs. Superculture® Pet Oral and Superculture® Pet Immune are our first two breakthrough ingredients, driving industry-leading efficacy and unlocking new marketing claims for brands.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Kingdom is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Curelab Veterinary, Inc. | Biotechnology | Seed | $33.7M | 71% |
| Ginkgo Bioworks Our mission is to make biology easier to engineer. | — | — | — | 71% |
| Suono Bio, Inc. | Biotechnology | Series A | $4.0M | 70% |
| Brown Foods Making 'REAL' Cow and Human Milk! | Biotech | — | — | 70% |
| JoJo Biotechnologies Co Ltd | Biotechnology | Series A | $17.6M | 70% |
| Superluminal Medicines, Inc. | Biotechnology | Series B | $22.0M | 70% |
| ImmunityBio, Inc. We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products. | Biotechnology | Growth/Late | $7.8B | 69% |
| Clover Biopharmaceuticals, Ltd. | Biotechnology | Series C | $8.9M | 69% |
See where Kingdom sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Kingdom, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.